Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study.

doi:10.1016/j.ygyno.2021.01.025

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study.

Gynecologic oncology - 1 Apr 2021

Leslie Kimberly K, Filiaci Virginia L, Mallen Adrianne R, Thiel Kristina W, Devor Eric J, Moxley Katherine, Richardson Debra, Mutch David, Secord Angeles Alvarez, Tewari Krishnansu S, McDonald Megan E, Mathews Cara, Cosgrove Casey, Dewdney Summer, Casablanca Yovanni, Jackson Amanda, Rose Peter G, Zhou XunClare, McHale Michael, Lankes Heather, Levine Douglas A, Aghajanian Carol

Abstract excerpt

BACKGROUND: Successfully combining targeted agents with chemotherapy is an important future goal for cancer therapy. However, an improvement in patient outcomes requires an enhanced understanding of the tumor biomarkers that predict for drug sensitivity. NRG Oncology/Gynecologic Oncology Group (GOG) Study GOG-86P was one of the first attempts to combine targeted agents (bevacizumab or temsirolimus) with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bevacizumab

Share to Carboplatin

Share to Clinical Trials, Phase II as Topic

Share to Paclitaxel

Share to Progression-Free Survival

Share to Randomized Controlled Trials as Topic

Share to Sirolimus

Source

Open in PubMed Open full text

Identifiers

PMID: 33541735
DOI: 10.1016/j.ygyno.2021.01.025
PMCID: PMC7994192

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study.PMID 33541735Read ↗

TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study.Semantic proximity Read ↗

Impact of TP53 somatic mutations on prognosis in endometrial cancer: a systematic review and meta-analysis.Semantic proximity Read ↗

A Primer on the Role of TP53 Mutation and Targeted Therapy in Endometrial Cancer.Semantic proximity Read ↗

Utility of molecular subtypes and genetic alterations for evaluating clinical outcomes in 1029 patients with endometrial cancer.Semantic proximity Read ↗

TP53 mutation and abnormal p53 expression in endometrial cancer: Associations with race and outcomes.Semantic proximity Read ↗

Met Mutation is a Potential Therapeutic Target for Advanced Endometrial Cancer Semantic proximity Read ↗

TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics.Semantic proximity Read ↗

Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study.Semantic proximity Read ↗

Strategies for Molecularly Enhanced Chemotherapy to Achieve Synthetic Lethality in Endometrial Tumors with Mutant p53Semantic proximity Read ↗

MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy.Semantic proximity Read ↗

Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With ERBB2/3 Amplification, Overexpression, or Mutation: Results From the TAPUR Study.Semantic proximity Read ↗

Characterization of TP53 and PI3K signaling pathways as molecular targets in gynecologic malignancies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.